Events

IDT reports significant growth for the March quarter April 29, 2025

Contract pharmaceutical manufacturer IDT Australia (ASX:IDT) has announced a 30.4 per cent increase in revenue growth for the three months ending March 2025.

Dimerix says FDA confirms proteinuria as acceptable endpoint for DMX-200 Phase 3 trial April 29, 2025

Dimerix (ASX:DXB) has provided an update on its ACTION3 Phase 3 clinical trial of DMX-200 in a rare kidney disease, Focal Segmental Glomerular Sclerosis.

Radiopharm Theranostics doses first patient in US Phase 2b imaging study of brain metastasis April 29, 2025

Radiopharm Theranostics (ASX:RAD) has announced the dosing of the first patient in its US Phase 2b imaging study of 18F-RAD101 in suspected recurrent brain metastasis.

Recce Pharmaceuticals enters research and development agreement with US defence April 29, 2025

Recce Pharmaceuticals (ASX:RCE) has entered into a Cooperative Research and Development Agreement with the US Army Medical Research Institute of Infectious Diseases, with partnership and funding from the Defense Threat Reduction Agency.

Atomo Diagnostics completes capital raise and undertakes restructure April 24, 2025

Atomo Diagnostics (ASX:AT1) has completed a share placement and says it will implement changes to its board and business operations to reflect its strategic and operational needs.

Chimeric Therapeutics announces the completion of entitlement offer April 24, 2025

Cell therapy company Chimeric Therapeutics (ASX:CHM) recently announced the investor participation in a non-renounceable entitlement offer to raise up to $3.2 million.

Orthocell appoints its first four US Remplir distributors and expects near-term sales April 23, 2025

Regenerative medicine company Orthocell (ASX:OCC) has appointed its first four US distributors of its nerve repair product Remplir.

Lumos secures additional US reimbursement coverage for FebriDx April 23, 2025

Lumos Diagnostics (ASX:LDX) has announced that it has received confirmation of reimbursement coverage from two additional Medicare Administrative Contractors (MACS), First Coast Service Options and Noridian Healthcare Solutions.

Mesoblast says Ryoncil payer coverage extended to over 100 million Americans April 22, 2025

Allogeneic cell therapy company Mesoblast (ASX:MSB) has announced expanded US payer coverage for its Ryoncil (remestemcel-L), the first mesenchymal stromal cell therapy approved by the US FDA.

Anatara provides update following completion of analysis of Phase 2 GaRP-IBS clinical trial April 22, 2025

Anatara Lifesciences (ASX:ANR) has updated investors on an analysis following the completion of Stage 2 of its GaRP-IBS (Irritable Bowel Syndrome) trial.

Neurizon announces the appointment of chief financial officer April 22, 2025

Clinical-stage company Neurizon Therapeutics (ASX:NUZ) has announced the appointment of Dan O’Connell as chief financial officer.

Recce Phase 2 trial receives additional approval for treating diabetic patients with topical gel April 22, 2025

Recce Pharmaceuticals (ASX:RCE) has received Human Research Ethics Approval (HREC) to enrol up to 20 additional patients with Diabetic Foot Infections in its Phase 2 trial of R327G.

Most Read

IDT reports significant growth for the March quarter

Dimerix says FDA confirms proteinuria as acceptable endpoint for DMX-200 Phase 3 trial

Recce Pharmaceuticals enters research and development agreement with US defence

Radiopharm Theranostics doses first patient in US Phase 2b imaging study of brain metastasis

New Stories

IDT reports significant growth for the March quarter

Dimerix says FDA confirms proteinuria as acceptable endpoint for DMX-200 Phase 3 trial

Radiopharm Theranostics doses first patient in US Phase 2b imaging study of brain metastasis

Recce Pharmaceuticals enters research and development agreement with US defence

Atomo Diagnostics completes capital raise and undertakes restructure

Chimeric Therapeutics announces the completion of entitlement offer

Orthocell appoints its first four US Remplir distributors and expects near-term sales

Sign In

Most Read

IDT reports significant growth for the March quarter

Dimerix says FDA confirms proteinuria as acceptable endpoint for DMX-200 Phase 3 trial

Recce Pharmaceuticals enters research and development agreement with US defence

Radiopharm Theranostics doses first patient in US Phase 2b imaging study of brain metastasis

Follow Us

New Stories

IDT reports significant growth for the March quarter

Dimerix says FDA confirms proteinuria as acceptable endpoint for DMX-200 Phase 3 trial

Radiopharm Theranostics doses first patient in US Phase 2b imaging study of brain metastasis

Recce Pharmaceuticals enters research and development agreement with US defence

Atomo Diagnostics completes capital raise and undertakes restructure

Chimeric Therapeutics announces the completion of entitlement offer

Orthocell appoints its first four US Remplir distributors and expects near-term sales